A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway	Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, breast cancer, breast disorder, breast neoplasm, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, gastric cancer, gastric neoplasm, intestinal disorder, male reproductive organ cancer, male reproductive system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm, prostate cancer, prostate disorder, rectal disorder, skin disorder, stomach disorder, uterine disorder	Not yet recruiting	Phase 1	2024-09-27		NCT06614751

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Danatlas Pharmaceuticals Co., Ltd	3

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College	Beijjing	China	1
Peking University Cancer Hospital and Institute	Beijing	China	1